Stock info Novavax Inc | Filter  Basic-Info

Novavax Inc

The core activities of Novavax Inc are in the biotech sector. The past 10 years the (international) industry gained at around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year was a profitable year for the Novavax Inc investors

The stock lost over the past 12 months at around 84 percent. Over the past 5 years Novavax Inc' stock rose at around 9 percent in value. Novavax Inc's revenues between 2011 and 2015 were very volatile through the time and moved between 22,08 million dollars and 36,25 million dollars. Novavax Inc's net results between 2011 and 2015 were far from constant and moved between -19,36 million dollars and -156,94 million dollars.

Over the past 5 years the American company paid out dividends.

Novavax Inc financed with relatively low debt

At the end of 2015 the biotech company's balance sheet was worth 386,04 million dollars. At the end of 2015 the total debt positon equaled 93,37 million dollars. This is around 24,19 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around -10. So investors paid -10 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 2,11 billion dollars. At the end of 2015 the American company had around 262,25 million stocks listed.

On this page you can find all Novavax Inc's financial reports. More information about Novavax Inc can be found it's website. .